TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06291779

Intervention type: DEVICE
Intervention: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
Description: * Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.

Intervention type: DEVICE
Intervention: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
Description: * Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.
Study: NCT04614532

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Pressor Test
Description: consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Pressor Test
Description: consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test.

Intervention type: OTHER
Group type: OTHER
Intervention: digital sensor of Nociception Level Index
Description: placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: digital sensor of Nociception Level Index
Description: placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
Study: NCT04716725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Given IV
Study: NCT06335836

Intervention type: BEHAVIORAL
Intervention: social isolation
Description: social isolation (0≤LSNS-6≤12)
Study: NCT05147506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNRM DTx
Description: A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Comparison
Description: A mobile application that consists of psychoeducational material regarding depression and brain injury.
Study: NCT05246787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding
Description: nonphamacological methods

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Breastfeeding and Shotblocker
Description: combined Breastfeeding and Shotblocker device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shotblocker
Description: it is a small plastic tool
Study: NCT03745417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Description: Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
Study: NCT05612087

Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Confocal laser endomicroscopy at jejunum, duodenum and stomach
Study: NCT06330350

Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
Study: NCT06336031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood-injection-injury (BII) phobia stimuli
Description: 498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: neutral stimuli
Description: 498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
Study: NCT06084390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary care + booster session (intervention)
Description: Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
Study: NCT04716725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET
Study: NCT04199026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given via microdevice
Study: NCT04603014

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Interdialytic peritoneal ultrafiltration with 10% dextrose solution
Description: Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
Study: NCT04199026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given via microdevice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Delivery Microdevice
Description: Undergo percutaneous implantation of drug delivery microdevice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given via microdevice

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Given via microdevice
Study: NCT05490654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal Massage delivered by manual method or by Mowoot device
Study: NCT06084390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary care (control)
Description: Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
Study: NCT04199026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given via microdevice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given via microdevice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given via microdevice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: Given via microdevice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given via microdevice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given via microdevice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given via microdevice
Study: NCT04466007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose allogeneic mesenchymal stromal cells
Description: Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
Study: NCT06052735

Intervention type: OTHER
Group type: OTHER
Intervention: Correlation research
Description: The relationship among pain perception, temporomandibular disorder severity and spine health
Study: NCT04466007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose allogeneic mesenchymal stromal cells
Description: Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0,9% physiological saline
Study: NCT06584656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise condition
Description: Aerobic session will last 30 min. The average intensity of the aerobic sessions will be 60-70% of the Maximal Heart Rate. Therefore, participant will perform a continuous moderate intensity aerobic bout of exercise on a cycle ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise condition
Description: Resistance exercise will last 30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion from 0-10). The bout of resistance exercise will include a combination of upper and lower body exercises using elastic bands and the participants' body weight as the primary resistance. Eight different exercises will be performed per set, with 40 seconds per exercise, for a total of 3 sets. The exercises are based on basic movement patterns and include: glute bridge, front plank, standing face pull, incline push-up, squat, pallof press, walking lunge and seated shoulder press.
Study: NCT06139354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: decision aid
Description: A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making.
Study: NCT05232929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Participants will receive risdiplam orally.
Study: NCT05230602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: opuntia (tzabar fruit)
Description: consuming of the tzabar fruit twice a day
Study: NCT05446207

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy and Task-oriented Training
Description: The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy and Task oriented Training with Routine Physiotherapy
Description: Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
Study: NCT05005416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOALS Intervention
Description: Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Physical Therapy
Description: Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
Study: NCT06317844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Writing Intervention
Description: This behavioral intervention will require participants to write about certain aspects of their lives.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Writing Intervention
Description: This behavioral intervention will require participants to write about certain aspects of their lives.
Study: NCT06028464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine
Study: NCT06535373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Both groups will undergo a 6-week training intervention with training 2x a week, after which grip strength and other relevant outcomes will be measured and compared. Exercise sessions will be at least 48 hours apart. Participants will be allowed to continue with their normal exercise routine outside of the study.
Study: NCT06640530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-263
Description: BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo
Description: Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
Study: NCT06641713

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE was carried out under the guidance of digital subtraction angiography, and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The emulsion of the selected drug and the embolization agents was therefore injected infused into tumor-feeding arteries via the selective microcatheter. A final arteriography confirmed the success of the procedure. The endpoint of the TACE procedure was reached when there was no flow in the tumor-feeding vessels.

Intervention type: PROCEDURE
Intervention: HAIC
Description: HAIC was carried out under the guidance of digital subtraction angiography, 990and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
Study: NCT05102370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
Study: NCT04089696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExSprion
Description: The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
Study: NCT05499715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ScTIL injection
Description: Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion.
Study: NCT05737589

Intervention type: RADIATION
Intervention: Whole-brain radiotherapy
Description: Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
Study: NCT06569823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection
Study: NCT05100459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasture-raised whey protein
Description: 25 grams of protein delivered 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional whey protein
Description: 25 grams of protein delivered 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Iso-caloric placebo taken 3 times daily like the protein supplementation
Study: NCT04683588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Coaching
Description: Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
Study: NCT05227131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
Study: NCT05644886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FP Training and Technical Support
Description: Same as in Intervention arm description
Study: NCT06569823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Formulation for injection